ASH 2025: Legend Biotech CEO Ying Huang discusses new long-term Carvykti data, looming competition, a CD19+CD20 γδ program, and in vivo CAR-T

He says he is confident in the commercial leadership profile that Carvykti has established, and walks us through potential follow-on pipeline programs.